Track topics on Twitter Track topics that are important to you
This KOL Insight briefing focuses on KOLs views of Patient Niches in IBD.
Perceptions on patient niches and treatments of fistulizing Crohn's disease
Perceptions on patient niches and treatments in smallbowel Crohn's disease
Perceptions on patient niches and treatments in pouchitis
Perceptions on patient niches and treatments in acute severe UC
Most KOLs were unsure of the efficacy profile for JAK inhibitors in the treatment of fistulizing Crohn's disease
Most KOLs flagged the need for a targeted therapy that prevents longterm complications of SBCD
Most KOLs noted that up to 50% of UC patients experience pouchitis after surgery, with antibiotics typically used before biologics.
The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders KOLs.
In total, we conducted interviews with 10 KOLs
5 Europebased 5 N. Americabased
Interviews performed during July 2018
KOL data is analyzed to produce
Charts summarizing KOL opinions
Chart callouts of key information details
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on Patient Niches in IBD
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of IBD
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.NEXT ARTICLE
Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system. Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...